Biopharmaceuticals
Licensing
News Release - February 10, 2016
Cocrystal Pharma Announces In-Licensing of CRISPR Cas Technologies for Hepatitis B Virus and Human Papilloma Virus
Source: Cocrystal Pharma
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.